BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA

BML Capital Management LLC purchased a new position in ImageneBio, Inc. (NASDAQ:IMA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 182,509 shares of the company’s stock, valued at approximately $1,487,000. ImageneBio makes up 1.1% of BML Capital Management LLC’s investment portfolio, making the stock its 12th biggest holding. BML Capital Management LLC owned 4.55% of ImageneBio as of its most recent filing with the Securities & Exchange Commission.

Separately, Vanguard Group Inc. bought a new stake in shares of ImageneBio during the 3rd quarter worth about $1,902,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Trading Up 4.5%

NASDAQ:IMA opened at $7.00 on Monday. The company has a 50-day moving average of $6.74 and a 200-day moving average of $8.34. The firm has a market cap of $78.26 million, a price-to-earnings ratio of -0.87 and a beta of 0.43. ImageneBio, Inc. has a twelve month low of $5.70 and a twelve month high of $18.12.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Wall Street Zen lowered shares of ImageneBio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Wedbush downgraded ImageneBio from a “neutral” rating to an “underperform” rating in a research report on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $26.50.

Insider Transactions at ImageneBio

In related news, Director Joseph P. Slattery purchased 16,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The shares were bought at an average price of $5.99 per share, with a total value of $95,840.00. Following the completion of the acquisition, the director owned 16,000 shares of the company’s stock, valued at approximately $95,840. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 5.94% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.